Anavex Life Sciences Corp. announced that data from its ATTENTION-AD trial, demonstrating positive results for oral blarcamesine (ANAVEX®2-73) in early Alzheimer's disease, was presented at the AD/PD™ 2025 Conference. The data showed over three years of continuous treatment with blarcamesine significantly ameliorated clinical decline, providing continued clinically meaningful benefit for patients.
Continued blarcamesine treatment for up to four years demonstrated a good comparative safety profile, with no associated neuroimaging adverse events and no treatment-related deaths. A prespecified delayed-start analysis indicated a disease-modifying effect, with a significant difference in ADAS-Cog13 (LS mean difference -3.83, P = 0.0165) and ADCS-ADL (LS mean difference +4.30, P = 0.0206) up to Week 192, favoring early and continuous treatment.
An additional analysis confirmed that blarcamesine treatment with few or no interrupted days resulted in an improved treatment effect for both cognition (ADAS-Cog13 LS mean difference -4.20, P = 0.0083) and function (ADCS-ADL LS mean difference +5.75, P = 0.0015) at Week 192. These results underscore the importance of early and consistent long-term treatment for chronic Alzheimer’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.